Catalyst Funds Management’s BridgeBio Oncology BBOT Stock Holding History
Bought
Maintained
Sold
Other funds holding BBOT
Catalyst Funds Management's BBOT Position: Q3 2026 in Review
Catalyst Funds Management opened a new position in BridgeBio Oncology (BBOT) in Q3 2026: 30,601 shares worth $125K. The stake represents 0.01% of the portfolio and ranks #552 among its holdings.
44 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.
- Catalyst Funds Management held 30,601 shares of BridgeBio Oncology worth $125K as of Q3 2026.
- BridgeBio Oncology was a new Catalyst Funds Management position in Q3 2026.
- BridgeBio Oncology made up 0.01% of Catalyst Funds Management's portfolio in Q3 2026, its #552 holding.
- 44 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.
Based on Catalyst Funds Management's 13F filing for Q3 2026, filed 12 Nov 2026.